MY140503A - Formulation of sec1 mutated protein and method for formulation of the same - Google Patents
Formulation of sec1 mutated protein and method for formulation of the sameInfo
- Publication number
- MY140503A MY140503A MYPI20055582A MYPI20055582A MY140503A MY 140503 A MY140503 A MY 140503A MY PI20055582 A MYPI20055582 A MY PI20055582A MY PI20055582 A MYPI20055582 A MY PI20055582A MY 140503 A MY140503 A MY 140503A
- Authority
- MY
- Malaysia
- Prior art keywords
- formulation
- sec1
- present
- mutant protein
- mastitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20040099624 | 2004-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY140503A true MY140503A (en) | 2009-12-31 |
Family
ID=36565261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI20055582A MY140503A (en) | 2004-12-01 | 2005-11-29 | Formulation of sec1 mutated protein and method for formulation of the same |
Country Status (5)
Country | Link |
---|---|
KR (1) | KR100729954B1 (fr) |
AR (1) | AR054710A1 (fr) |
MY (1) | MY140503A (fr) |
PE (1) | PE20061171A1 (fr) |
WO (1) | WO2006059846A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2547361T3 (da) | 2010-03-17 | 2020-11-23 | Socpra Sciences Et Genie Sec | Bakterielle vaccinekomponenter fra staphylococcus aureus og anvendelser deraf |
UY37448A (es) | 2016-10-21 | 2018-03-23 | Socpra Sciences Et Genie Sec | Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus |
KR102061735B1 (ko) * | 2018-06-08 | 2020-01-02 | 대한민국(농림축산식품부 농림축산검역본부장) | 황색포도알균 약독화 장독소 및 세포독소 재조합 단백질을 포함하는 백신 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100201352B1 (ko) * | 1995-03-16 | 1999-06-15 | 성재갑 | 단일주사 백신 제형 |
PL200954B1 (pl) * | 1999-01-18 | 2009-02-27 | Lg Life Sciences | Lipofilowe mikrocząsteczki zawierające lek proteinowy lub peptydowy i preparat zawierający te mikrocząsteczki |
ATE299696T1 (de) * | 2000-05-12 | 2005-08-15 | Pharmacia & Upjohn Co Llc | Impfstoffzusammensetzung und verfahren zur herstellung derselben sowie verfahren zur impfung von wirbeltieren |
-
2005
- 2005-11-16 WO PCT/KR2005/003871 patent/WO2006059846A1/fr active Application Filing
- 2005-11-16 KR KR1020050109644A patent/KR100729954B1/ko not_active IP Right Cessation
- 2005-11-18 PE PE2005001357A patent/PE20061171A1/es not_active Application Discontinuation
- 2005-11-29 MY MYPI20055582A patent/MY140503A/en unknown
- 2005-11-30 AR ARP050105011A patent/AR054710A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE20061171A1 (es) | 2006-12-18 |
KR20060061225A (ko) | 2006-06-07 |
AR054710A1 (es) | 2007-07-11 |
WO2006059846A1 (fr) | 2006-06-08 |
KR100729954B1 (ko) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016226280B2 (en) | Transmucosal and transdermal delivery systems | |
WO2009043527A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009046834A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009040024A3 (fr) | Utilisation d'un peptide comme agent thérapeutique | |
US10864188B2 (en) | Anti-microbial composition | |
WO2009033683A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009039992A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033668A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
TW200640486A (en) | Composition | |
WO2009033736A3 (fr) | Utilisation d'un peptide comme agent thérapeutique | |
NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
WO2009040029A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009046845A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009043454A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033791A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2009033780A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
JP2017533972A5 (fr) | ||
WO2009039957A3 (fr) | Utilisation d'un peptide en tant qu'agent thérapeutique | |
WO2006115770A3 (fr) | Preparations pharmaceutiques d'olazanpine en comprimes a desintegration orale | |
MY140503A (en) | Formulation of sec1 mutated protein and method for formulation of the same | |
EP3634583A1 (fr) | Implant à action prolongée pour le traitement de maladies infectieuses | |
Mishra | An investigation on the approach to target lipopolysaccharide through polymeric capped nano-structured formulation for the management of sepsis | |
WO2006089120A3 (fr) | Compositions, procedes d'utilisation et de preparation de 2,6-diisopropylphenol et d'analogues de ce dernier pour traiter une liaison ischemique | |
MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. | |
EP4238555A3 (fr) | Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil |